Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib safety study in Indian patients with ovarian cancer
NCT06887933Phase 4Not yet recruiting
- Sponsor
- GSK
- Start
- Apr 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of niraparib in Epithelial Ovarian Cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by GSK. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
niraparib
03
Conditions
Epithelial Ovarian Cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06887933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06887933.